company background image
EGRX

Eagle PharmaceuticalsNasdaqGM:EGRX Stock Report

Market Cap

US$660.1m

7D

-3.2%

1Y

12.5%

Updated

27 Oct, 2021

Data

Company Financials +
EGRX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth4/6
Past Performance2/6
Financial Health5/6
Dividends0/6

EGRX Overview

Eagle Pharmaceuticals, Inc., a biotechnology pharmaceutical company, focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States.

Rewards

Earnings are forecast to grow 108.4% per year

Became profitable this year

Risk Analysis

No risks detected for EGRX from our risk checks.

Eagle Pharmaceuticals Competitors

Hikma Pharmaceuticals

LSE:HIK

UK£5.7b

Endo International

NasdaqGS:ENDP

US$1.0b

Price History & Performance

Summary of all time highs, changes and price drops for Eagle Pharmaceuticals
Historical stock prices
Current Share PriceUS$50.64
52 Week HighUS$36.48
52 Week LowUS$58.25
Beta0.78
1 Month Change-7.73%
3 Month Change8.65%
1 Year Change12.46%
3 Year Change2.84%
5 Year Change-25.64%
Change since IPO294.70%

Recent News & Updates

Jul 06
Shareholders May Be Wary Of Increasing Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) CEO Compensation Package

Shareholders May Be Wary Of Increasing Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) CEO Compensation Package

The results at Eagle Pharmaceuticals, Inc. ( NASDAQ:EGRX ) have been quite disappointing recently and CEO Scott Tarriff...

Jun 16

Eagle Pharmaceuticals: A Potential Reopening Play

Eagle Pharmaceuticals has felt the impact of COVID-19, and the earnings reports have reflected that. As a result, the share price has taken a beating over the past year. The company expects to see its earnings improve over the remainder of 2021 as the country begins to reopen and patients resume their chemo treatments. In addition to being a reopening play, I expect EGRX to be a great growth story in the coming years as they launch PEMFEXY and vasopressin in the coming quarters. I discuss my leading downside risk and reveal my plans for establishing a position in EGRX.

Shareholder Returns

EGRXUS BiotechsUS Market
7D-3.2%1.5%0.9%
1Y12.5%17.8%33.4%

Return vs Industry: EGRX underperformed the US Biotechs industry which returned 17.8% over the past year.

Return vs Market: EGRX underperformed the US Market which returned 33.4% over the past year.

Price Volatility

Is EGRX's price volatile compared to industry and market?
EGRX volatility
EGRX Beta0.78
Industry Beta0.98
Market Beta1

Stable Share Price: EGRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: EGRX's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2007106Scott Tarriffhttps://www.eagleus.com

Eagle Pharmaceuticals, Inc., a biotechnology pharmaceutical company, focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock.

Eagle Pharmaceuticals Fundamentals Summary

How do Eagle Pharmaceuticals's earnings and revenue compare to its market cap?
EGRX fundamental statistics
Market CapUS$660.09m
Earnings (TTM)US$18.31m
Revenue (TTM)US$189.22m

36.2x

P/E Ratio

3.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
EGRX income statement (TTM)
RevenueUS$189.22m
Cost of RevenueUS$46.14m
Gross ProfitUS$143.08m
ExpensesUS$124.77m
EarningsUS$18.31m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)1.40
Gross Margin75.62%
Net Profit Margin9.68%
Debt/Equity Ratio15.1%

How did EGRX perform over the long term?

See historical performance and comparison

Valuation

Is Eagle Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

36.23x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: EGRX ($50.64) is trading above our estimate of fair value ($30.2)

Significantly Below Fair Value: EGRX is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: EGRX is poor value based on its PE Ratio (36.2x) compared to the US Biotechs industry average (24x).

PE vs Market: EGRX is poor value based on its PE Ratio (36.2x) compared to the US market (18.1x).


Price to Earnings Growth Ratio

PEG Ratio: EGRX is good value based on its PEG Ratio (0.3x)


Price to Book Ratio

PB vs Industry: EGRX is overvalued based on its PB Ratio (3.4x) compared to the US Biotechs industry average (2.9x).


Future Growth

How is Eagle Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

108.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: EGRX's forecast earnings growth (108.4% per year) is above the savings rate (2%).

Earnings vs Market: EGRX's earnings (108.4% per year) are forecast to grow faster than the US market (14.7% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: EGRX's revenue (10.5% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: EGRX's revenue (10.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if EGRX's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Eagle Pharmaceuticals performed over the past 5 years?

-34.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EGRX has high quality earnings.

Growing Profit Margin: EGRX became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: EGRX's earnings have declined by 34.8% per year over the past 5 years.

Accelerating Growth: EGRX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: EGRX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: EGRX's Return on Equity (9.4%) is considered low.


Financial Health

How is Eagle Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: EGRX's short term assets ($175.5M) exceed its short term liabilities ($44.7M).

Long Term Liabilities: EGRX's short term assets ($175.5M) exceed its long term liabilities ($24.7M).


Debt to Equity History and Analysis

Debt Level: EGRX's debt to equity ratio (15.1%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if EGRX's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: EGRX's debt is well covered by operating cash flow (151.4%).

Interest Coverage: EGRX's interest payments on its debt are well covered by EBIT (20.1x coverage).


Balance Sheet


Dividend

What is Eagle Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate EGRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate EGRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EGRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EGRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EGRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Scott Tarriff (61 yo)

14.75yrs

Tenure

US$9,469,433

Compensation

Mr. Scott L. Tarriff founded Eagle Pharmaceuticals Inc. in January 2007 and has been its Chief Executive Officer since January 2007, where he has helped build its market cap and has successfully marketed v...


CEO Compensation Analysis

Compensation vs Market: Scott's total compensation ($USD9.47M) is above average for companies of similar size in the US market ($USD2.26M).

Compensation vs Earnings: Scott's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: EGRX's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

Experienced Board: EGRX's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Eagle Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Eagle Pharmaceuticals, Inc.
  • Ticker: EGRX
  • Exchange: NasdaqGM
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$660.094m
  • Shares outstanding: 13.10m
  • Website: https://www.eagleus.com

Number of Employees


Location

  • Eagle Pharmaceuticals, Inc.
  • 50 Tice Boulevard
  • Suite 315
  • Woodcliff Lake
  • New Jersey
  • 7677
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/27 22:09
End of Day Share Price2021/10/27 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.